Current treatment options: relief of symptoms and ultimate recovery

References

• Kessler RC, Chiu WT, Demler O. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 617–27
   PubMed Web of Science ®Google Scholar
• Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000?. J Clin Psychiatry 2003; 64: 1465–75
   PubMed Web of Science ®Google Scholar
• Kennedy SH, Eisfeld BS, Meyer JH, Bagby RM. Antidepressants in clinical practice: limitations of assessment methods and drug response. Hum Psychopharmacol 2001; 16: 105–14
   PubMed Web of Science ®Google Scholar
• Kennedy, SH, Beaulieu, C, Lam, R. Canadian Depression Study. Presented at Canadian Psychiatric Association Annual Meeting, October, 2004, Montreal, Canada.
   Google Scholar
• Global Alliance of Mental Illness Advocacy Networks. AHEAD survey, Lundbeck, Copenhagen, Denmark, 2003.
   Google Scholar
• Wade, AG. Poster presented at DURG/British Society for Psychopharmacology, 2005.
   Google Scholar
• Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23: 56–62
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382–9
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, Farabaugh AH, Alpert JE. Timing of onset of antidepressant response with fluoxetine treatment. Am J Psychiatry 2000; 157: 1423–8
   PubMed Web of Science ®Google Scholar
• Blier P. Pharmacology of rapid-onset antidepressant treatment strategies. J Clin Psychiatry 2001; 62(Suppl 15)12–7
   PubMed Web of Science ®Google Scholar
• Stahl, SM, Nierenberg, AA, Gorman, JM. Evidence of early onset of antidepressant effect in randomized controlled trials. J Clin Psychiatry 2001;62(Suppl 4): 17–23; discussion 37–40.
   PubMedGoogle Scholar
• Blier P. Why treat depression differently from other medical problems?. J Psychiatry Neurosci 2002; 27: 231–2
   Google Scholar
• Wade AG, Lemming O, Hedegaard K. Escitalopram 10 mg/day is effective and well-tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2002; 17: 95–102
   PubMed Web of Science ®Google Scholar
• Burke WJ, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients. J Clin Psychiatry 2002; 63: 331–6
   PubMed Web of Science ®Google Scholar
• Lepola UM, Loft H, Reines EH. Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care. Int Clin Psychopharmacol 2003; 18: 211–7
   PubMed Web of Science ®Google Scholar
• Lepola UM, Wade A, Andersen HF. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychpharmacol 2004; 19: 149–55
   PubMed Web of Science ®Google Scholar
• Kasper S, Spadone C, Verpillat P, Angst J. Onset of action of escitalopram compared with other antidepressants: results of a pooled analysis. Int Clin Psychopharmacol 2006;Mar; 21(2)105–10
   Google Scholar
• Rapaport MH, Bose A, Zheng H. Escitalopram continuation treatment prevents relapse of depressive episodes. J Clin Psychiatry 2004; 65: 44–9
   PubMed Web of Science ®Google Scholar
• Colonna L, Reines EH, Andersen HF. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder. Curr Med Res Opin 2005;Oct; 21(10)1659–68
   PubMed Web of Science ®Google Scholar
• Reines, EH, Andersen, HF, de Swart, H, Kasper, S. Tolerability of escitalopram in the treatment of depressed elderly patients. Poster presented at the 45th Annual Meeting of the Scandinavian College of Neuro-Psychopharmacology. 21–24 April, 2004.
   Google Scholar
• Montgomery, SA, Marino, V, Bielski, RJ. Escitalopram versus venlafaxine XR in the treatment of major depressive disorder. Poster presented at the International Congress of the World Psychiatric Association, Florence, Italy, 10–13 November, 2004.
   Google Scholar
• Bielski RJ, Ventura D, Chang C-C. A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder. J Clin Psychiatry 2004; 65: 1190–6
   PubMed Web of Science ®Google Scholar
• Alexopoulos, G, Gordon, J, Zhang, D. A placebo-controlled trial of escitalopram and sertraline in the treatment of MDD. Poster presented at the 43rd Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, 12–16 December, 2004.
   Google Scholar
• Diaz-Martinez A, Benassinni O, Ontiveros A, et al. A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients. Clin Ther 1998; 20: 467–76
   PubMed Web of Science ®Google Scholar
• Zanardi R, Franchini L, Serretti A, et al. Venlafaxine versus fluvoxamine in the treatment of delusional depression: A pilot double-blind controlled study. J Clin Psychiatry 2000; 61: 26–9
   PubMed Web of Science ®Google Scholar
• Watkins, L, Davidson, JRT, Connor, KM, et al., Effects of paroxetine and venlafaxine on heart rate variability in depression. Eur Neuropsychopharmacol 2003;13(Suppl 4):S274, Abstract P1.233.
   Google Scholar
• Shelton C, Entsuah R, Padmanabhan SK, Vinall PE. Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo. Int Clin Psychopharmacol 2005; 20: 233–8
   PubMed Web of Science ®Google Scholar
• Thase, ME, Entsuah, R, Ahmed, S, et al. Meta- and funnel-plot analyses of studies comparing venlafaxine and SSRIs: The evidence revisited. Poster presented at the American College of Neuropsychopharmacology, San Juan, Puerto Rico, 12–16 December, 2004.
   Google Scholar
• Kennedy SH, Andersen HF, Lam R. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci 2006; 31: 122–31
   PubMed Web of Science ®Google Scholar
• Muller MJ, Himmerich H, Kienzle B, Szegedi A. Differentiating moderate and severe depression using the Montgomery-Asberg depression rating scale (MADRS). J Affect Disord 2003; 77: 255–60
   PubMed Web of Science ®Google Scholar
• Angst J, Amrein R, Stabl M. Moclobemide and tricyclic antidepressants in severe depression: Meta-analysis and prospective studies. J Clin Psychopharmacol 1995; 15(4 Suppl 2)16–23S
   Google Scholar
• Schatzberg AF. Antidepressant effectiveness in severe depression and melancholia. J Clin Psychiatry 1999; 60(Suppl 4)14–22
   PubMedGoogle Scholar
• Azorin JM, Llorca PM, Despiegel N, Verpillat P. Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder. Encephale 2004; 30: 158–66
   PubMed Web of Science ®Google Scholar
• Bielski, RJ, Ventura, D, Chang, C-C. A double-blind comparison of escitalopram with venlafaxine XR in the treatment of major depressive disorder. Poster presented at 16th Congress of the European College of Neuropsychopharmacology, Prague Czech Republic, 20–24 September, 2003.
   Google Scholar